Search - tctmd.com

Displaying 221 - 240 of 417

Sort: Relevancy | Date

Presentation TCT 2016

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., John G. Webb

November 01, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

News Conference News TCT 2016

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Todd Neale

November 01, 2016

Presentation TCT 2016

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Presenter: Neil E. Moat, John G. Webb, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

Presenter: Neil E. Moat, John G. Webb, Ian T. Meredith

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe LV Dysfunction

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Qi Zhang

October 31, 2016

Presentation TCT 2016

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Presenter: Neil E. Moat, John G. Webb, Marina Urena

October 31, 2016

Presentation TCT 2016

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Presenter: William A. Gray, Stephan Windecker, John R. Laird Jr.

October 31, 2016

Presentation TCT 2016

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

Presenter: Neil E. Moat, John G. Webb, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

Presenter: Neil E. Moat, John G. Webb, Alexandra J. Lansky

October 31, 2016

Presentation TCT 2016

ACT I Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Klaus D. Mathias

October 31, 2016

Presentation TCT 2016

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

Presenter: William A. Gray, Stephan Windecker, Kenneth Rosenfield

October 31, 2016

Presentation TCT 2016

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

Presenter: Neil E. Moat, John G. Webb, Adam B. Greenbaum

October 31, 2016

Presentation TCT 2016

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

Presenter: Neil E. Moat, John G. Webb, Stephen R. Ramee

October 31, 2016

Presentation TCT 2016

CTSN Severe MR 2-Year Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Patrick M. McCarthy

October 31, 2016

Presentation TCT 2016

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Presenter: Neil E. Moat, John G. Webb, Pieter R. Stella

October 31, 2016

Presentation TCT 2016

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Presenter: William A. Gray, Stephan Windecker, Michael Argenziano

October 31, 2016

Presentation TCT 2016

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

Presenter: Neil E. Moat, John G. Webb, Eric Van Belle

October 31, 2016

Presentation TCT 2016

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Presenter: Neil E. Moat, John G. Webb, Scott Lim

October 31, 2016

Advertisement

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

My Most Challenging Case 2016: Severe LV Dysfunction

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

ACT I Critique: Pro and Con

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

CTSN Severe MR 2-Year Critique: Pro and Con

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content